Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ascorbic acid inhibits PMP22 expression by reducing cAMP levels.

Ferdinand Kaya1, Sophie Belin, Patrice Bourgeois

  • 1INSERM UMR491, Centre de Thérapie Génique, Génomique et de Biothérapies (CTGGB), IPHM-IFR125, Faculté de Médecine de la Timone, 27 bd Jean Moulin, 13385 Marseille cedex 5, France.

Neuromuscular Disorders : NMD
|February 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapie·2026
Same author

Pharmaco-metabolomics and metabolomics: A new tool in precision medicine?

Therapie·2026
Same author

Patient-Reported Outcomes in Early-Phase Oncology Clinical Trials: A Stepping Stone to a Patient-Centered Drug Development.

The patient·2025
Same author

PMP2 Enhances Schwann Cell Metabolism and Promotes Myelination.

Journal of neurochemistry·2025
Same author

Genetics and cancer-related Laminopathies: Involvement of Lamins and Lamin-Chromatin Interactions.

Sub-cellular biochemistry·2025
Same author

Shared Lineage, Distinct Outcomes: Yap and Taz Loss Differentially Impact Schwann and Olfactory Ensheathing Cell Development Without Disrupting GnRH-1 Migration.

Glia·2025
Same journal

Aquatic training improves muscle strength and functional mobility in adults with myotonic dystrophy type 1: a pilot randomized trial.

Neuromuscular disorders : NMD·2026
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
See all related articles

High doses of ascorbic acid may treat Charcot-Marie-Tooth (CMT) disease by repressing PMP22 gene expression. This vitamin

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Charcot-Marie-Tooth (CMT) syndrome is a common inherited peripheral neuropathy.
  • CMT type 1A (CMT1A), accounting for 50% of CMT cases, is typically caused by PMP22 gene triplication.
  • Previous studies suggested high-dose ascorbic acid may improve muscle strength in CMT animal models by repressing PMP22 expression.

Purpose of the Study:

  • To investigate the mechanism by which ascorbic acid represses PMP22 gene expression.
  • To determine if ascorbic acid's effect on PMP22 is specific and dose-dependent.

Main Methods:

  • Experiments were conducted using an animal model of CMT.
  • The study analyzed the effects of ascorbic acid on intracellular cAMP levels and adenylate cyclase activity.

Related Experiment Videos

  • Ascorbic acid's effects were compared to other antioxidants.

    • Main Results:

    • Ascorbic acid was demonstrated to repress PMP22 gene expression.
    • This repression is mediated by effects on intracellular cAMP levels and adenylate cyclase activity.
    • The effect was dose-dependent and specific to ascorbic acid, not observed with other antioxidants.

    Conclusions:

    • Ascorbic acid exhibits novel properties that repress PMP22 gene expression.
    • These findings suggest a potential therapeutic strategy for CMT disease using ascorbic acid.
    • Further research into ascorbic acid's role in treating CMT is warranted.